{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:07:48Z","timestamp":1789715268713,"version":"4.0.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1124\/jpet.114.216283","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T06:23:10Z","timestamp":1405664590000},"page":"25-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["The \u03b17 Nicotinic Receptor Agonist ABT-107 Decreases l-Dopa\u2013Induced Dyskinesias in Parkinsonian Monkeys"],"prefix":"10.1016","volume":"351","author":[{"given":"Danhui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryka","family":"Quik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.114.216283_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","article-title":"Mammalian nicotinic acetylcholine receptors: from structure to function","volume":"89","author":"Albuquerque","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.114.216283_bib2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.bcp.2009.06.024","article-title":"Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination","volume":"78","author":"Anderson","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.114.216283_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00213-011-2393-2","article-title":"Efficacy and safety of the novel \u03b1\u2084\u03b2\u2082 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit\/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study","volume":"219","author":"Apostol","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.216283_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/npp.2012.194","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of \u03b14\u03b22 agonist ABT-894 in adults with ADHD","volume":"38","author":"Bain","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.114.216283_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/13543784.2012.651457","article-title":"New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson\u2019s disease: targeting glutamate and adenosine receptors","volume":"21","author":"Blandini","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.114.216283_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1124\/jpet.108.140897","article-title":"Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson\u2019s disease","volume":"327","author":"Bordia","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.216283_bib7","doi-asserted-by":"crossref","unstructured":"Bordia T, McIntosh JM, Quik M (2013) The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release. J Neurochem DOI: 10.1111\/jnc.12179 [published ahead of print].","DOI":"10.1111\/jnc.12179"},{"key":"10.1124\/jpet.114.216283_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0091-3057(96)00354-1","article-title":"Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo","volume":"57","author":"Briggs","year":"1997","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.114.216283_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-381328-2.00005-5","article-title":"New approaches to therapy","volume":"98","author":"Brotchie","year":"2011","journal-title":"Int Rev Neurobiol"},{"issue":"Suppl 3","key":"10.1124\/jpet.114.216283_bib10","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1002\/mds.22019","article-title":"Molecular mechanisms underlying levodopa-induced dyskinesia","volume":"23","author":"Calabresi","year":"2008","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.114.216283_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2011.07.070","article-title":"Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia","volume":"198","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.114.216283_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0079-6123(10)83011-0","article-title":"Maladaptive striatal plasticity in L-DOPA-induced dyskinesia","volume":"183","author":"Cenci","year":"2010","journal-title":"Prog Brain Res"},{"key":"10.1124\/jpet.114.216283_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0022-3565(24)37015-6","article-title":"ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys","volume":"283","author":"Decker","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.216283_bib14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1073\/pnas.1006511108","article-title":"Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice","volume":"108","author":"Ding","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.114.216283_bib15","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","article-title":"Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson\u2019s disease","volume":"26","author":"Duty","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1124\/jpet.114.216283_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fnbeh.2011.00071","article-title":"L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission","volume":"5","author":"Feyder","year":"2011","journal-title":"Front Behav Neurosci"},{"key":"10.1124\/jpet.114.216283_bib17","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.22473","article-title":"Serotonin and Parkinson\u2019s disease: on movement, mood, and madness","volume":"24","author":"Fox","year":"2009","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.114.216283_bib18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia","volume":"165","author":"Freedman","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.114.216283_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1517\/13543784.2012.633510","article-title":"\u03b17 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer\u2019s disease","volume":"21","author":"Geerts","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.114.216283_bib20","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.neuropharm.2010.12.032","article-title":"Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats","volume":"60","author":"Huang","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.216283_bib21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/jpet.111.182949","article-title":"Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors","volume":"338","author":"Huang","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.216283_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.111.184093","article-title":"Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson\u2019s disease: an approach to reducing dyskinesia without exacerbating parkinsonism?","volume":"339","author":"Huot","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.216283_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson\u2019s disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol Rev"},{"issue":"Suppl 1","key":"10.1124\/jpet.114.216283_bib24","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1353-8020(11)70038-4","article-title":"Striatal plasticity in Parkinson\u2019s disease and L-dopa induced dyskinesia","volume":"18","author":"Iravani","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1124\/jpet.114.216283_bib25","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1021\/jm070755h","article-title":"Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists","volume":"50","author":"Ji","year":"2007","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.114.216283_bib26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuropharm.2013.06.005","article-title":"TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque","volume":"73","author":"Johnston","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.216283_bib27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0026-895X(24)12066-4","article-title":"Alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release","volume":"58","author":"Kaiser","year":"2000","journal-title":"Mol Pharmacol"},{"issue":"Suppl 2","key":"10.1124\/jpet.114.216283_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JAD-2011-110173","article-title":"Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"24","author":"Kawamata","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1124\/jpet.114.216283_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainresbull.2012.11.003","article-title":"\u03b17 nicotinic acetylcholine receptors and their role in cognition","volume":"93","author":"Lendvai","year":"2013","journal-title":"Brain Res Bull"},{"key":"10.1124\/jpet.114.216283_bib30","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2174\/138945012800398937","article-title":"\u03b17-Nicotinic receptors and cognition","volume":"13","author":"Levin","year":"2012","journal-title":"Curr Drug Targets"},{"key":"10.1124\/jpet.114.216283_bib31","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/npp.2012.259","article-title":"A randomized exploratory trial of an \u03b1-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia","volume":"38","author":"Lieberman","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.114.216283_bib32","doi-asserted-by":"crossref","first-page":"7816","DOI":"10.1523\/JNEUROSCI.20-20-07816.2000","article-title":"Stress-level cortisol treatment impairs inhibitory control of behavior in monkeys","volume":"20","author":"Lyons","year":"2000","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.114.216283_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1074-7427(03)00044-3","article-title":"Early maternal availability and prefrontal correlates of reward-related memory","volume":"80","author":"Lyons","year":"2003","journal-title":"Neurobiol Learn Mem"},{"key":"10.1124\/jpet.114.216283_bib34","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1523\/JNEUROSCI.0324-04.2004","article-title":"Cognitive correlates of white matter growth and stress hormones in female squirrel monkey adults","volume":"24","author":"Lyons","year":"2004","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.114.216283_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1124\/jpet.110.167072","article-title":"In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107","volume":"334","author":"Malysz","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.216283_bib36","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bcp.2009.05.022","article-title":"Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain","volume":"78","author":"Marks","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.114.216283_bib37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00213-006-0441-0","article-title":"Guidelines on nicotine dose selection for in vivo research","volume":"190","author":"Matta","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.114.216283_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson\u2019s disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.114.216283_bib39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuropharm.2008.07.041","article-title":"Diversity of vertebrate nicotinic acetylcholine receptors","volume":"56","author":"Millar","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.216283_bib40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nm.2165","article-title":"Missing pieces in the Parkinson\u2019s disease puzzle","volume":"16","author":"Obeso","year":"2010","journal-title":"Nat Med"},{"key":"10.1124\/jpet.114.216283_bib41","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/0091270010370460","article-title":"Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers","volume":"51","author":"Othman","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.114.216283_bib42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuropharm.2013.03.038","article-title":"\u03b14\u03b22 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats","volume":"71","author":"Quik","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.114.216283_bib43","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bcp.2013.06.027","article-title":"Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice","volume":"86","author":"Quik","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.114.216283_bib44","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.21203","article-title":"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys","volume":"62","author":"Quik","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1124\/jpet.114.216283_bib45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nbd.2012.09.006","article-title":"Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function","volume":"50","author":"Quik","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.114.216283_bib46","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/mds.25594","article-title":"Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson\u2019s disease","volume":"28","author":"Quik","year":"2013","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.114.216283_bib47","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1471-4159.2006.04078.x","article-title":"Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates","volume":"98","author":"Quik","year":"2006","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.114.216283_bib48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0306-4522(00)00244-X","article-title":"Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration","volume":"100","author":"Quik","year":"2000","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.114.216283_bib49","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/pr.110.003269","article-title":"\u03b16\u03b22* and \u03b14\u03b22* nicotinic acetylcholine receptors as drug targets for Parkinson\u2019s disease","volume":"63","author":"Quik","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.114.216283_bib51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.nbd.2010.08.018","article-title":"L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V\/VI and increased GABA release in the substantia nigra reticulata","volume":"41","author":"Rangel-Barajas","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.114.216283_bib52","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.pain.2012.01.009","article-title":"Efficacy and safety of the \u03b14\u03b22 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain","volume":"153","author":"Rowbotham","year":"2012","journal-title":"Pain"},{"issue":"Suppl 1","key":"10.1124\/jpet.114.216283_bib53","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/S1353-8020(11)70039-6","article-title":"The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery","volume":"18","author":"Rylander","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1124\/jpet.114.216283_bib54","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1471-4159.2008.05831.x","article-title":"L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice","volume":"108","author":"Santini","year":"2009","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.114.216283_bib55","doi-asserted-by":"crossref","first-page":"e12322","DOI":"10.1371\/journal.pone.0012322","article-title":"Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia","volume":"5","author":"Santini","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1124\/jpet.114.216283_bib56","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","article-title":"Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia","volume":"27","author":"Santini","year":"2007","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.114.216283_bib57","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/mds.23732","article-title":"Etiology and pathogenesis of Parkinson\u2019s disease","volume":"26","author":"Schapira","year":"2011","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.114.216283_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson\u2019s disease","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Prog Neurobiol"},{"key":"10.1124\/jpet.114.216283_bib59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)37014-4","article-title":"ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties","volume":"283","author":"Sullivan","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.216283_bib60","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/mds.10183","article-title":"The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys","volume":"17","author":"Tan","year":"2002","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.114.216283_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pneurobio.2012.06.003","article-title":"Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson\u2019s disease","volume":"98","author":"Wang","year":"2012","journal-title":"Prog Neurobiol"},{"key":"10.1124\/jpet.114.216283_bib62","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/mds.23695","article-title":"Milestones in research on the pathophysiology of Parkinson\u2019s disease","volume":"26","author":"Wichmann","year":"2011","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.114.216283_bib63","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mds.25817","article-title":"ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson\u2019s disease","volume":"29","author":"Zhang","year":"2014","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.114.216283_bib64","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.113.207639","article-title":"Nicotinic receptor agonists reduce L-dopa-induced dyskinesias in a monkey model of Parkinson's disease","volume":"347","author":"Zhang","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.216283_bib65","doi-asserted-by":"crossref","first-page":"11655","DOI":"10.1523\/JNEUROSCI.0288-13.2013","article-title":"Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses","volume":"33","author":"Zhang","year":"2013","journal-title":"J Neurosci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524188039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524188039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.114.216283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:47:02Z","timestamp":1739987222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524188039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0022356524188039"],"URL":"https:\/\/doi.org\/10.1124\/jpet.114.216283","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The \u03b17 Nicotinic Receptor Agonist ABT-107 Decreases l-Dopa\u2013Induced Dyskinesias in Parkinsonian Monkeys","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.114.216283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}